Complementary and alternative medicine: evaluating its effectiveness in inflammatory bowel disease

Area of Science:

• Gastroenterology and Hepatology
• Integrative Medicine
• Clinical Research Methodology

Background:

• Complementary and alternative medicine (CAM) is frequently utilized by patients diagnosed with inflammatory bowel disease (IBD).
• Randomized controlled trials (RCTs) are considered the gold standard for evaluating treatment efficacy, but few exist for CAM in IBD and often have methodological limitations.
• The fundamental principles of many CAM therapies, emphasizing holistic approaches and individualized patient roles, may conflict with the structured protocols of RCTs.

Purpose of the Study:

• To highlight the challenges in evaluating CAM therapies for IBD using traditional research methods.
• To underscore the need for a deeper understanding of CAM use in IBD before initiating clinical trials.
• To identify key areas for future research regarding CAM therapies, their application, and patient outcomes in IBD.

Main Methods:

• Literature review and critical analysis of existing studies on CAM in IBD.
• Examination of the philosophical and practical discrepancies between CAM principles and RCT methodologies.
• Identification of knowledge gaps concerning specific CAM modalities, patient motivations, and practitioner approaches in IBD management.

Main Results:

• A significant gap exists in high-quality evidence for CAM efficacy in IBD.
• Standard RCT designs present inherent challenges when applied to holistic and individualized CAM treatments.
• There is a lack of comprehensive data on the types of CAM used, reasons for use, side effects, and practitioner-specific treatment protocols in IBD.

Conclusions:

• Further research is essential to understand the landscape of CAM use in IBD.
• Methodologies for evaluating CAM in IBD need to be adapted to respect the nature of these therapies.
• A comprehensive understanding of CAM use is a prerequisite for designing effective clinical trials in IBD.